• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Apellis Pharmaceuticals, Inc. - Common Stock (NQ:APLS)

24.14 -0.98 (-3.90%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Apellis Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
Apellis Pharmaceuticals Upgraded To Buy: Analyst Sees Potential In Syfovre's Strong Launch
December 05, 2023
BofA Securities analyst Tazeen Ahmad upgraded Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) to Buy from Neutral,  
Via Benzinga
14 Analysts Have This to Say About Apellis Pharmaceuticals
December 05, 2023
 
Via Benzinga
Block To Rally Around 54%? Here Are 10 Top Analyst Forecasts For Tuesday
December 05, 2023
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
Magnificent 7 Take Center Stage In Hedge Fund Portfolios: Analysts Warn Of Extreme Concentration
November 21, 2023
Hedge fund portfolios are intensifying their focus on technology stocks, with holdings in mega-cap tech reaching record levels. 
Via Benzinga
Why Is Apellis Pharmaceuticals Stock Trading Lower Today?
November 06, 2023
Shares of Apellis Pharmaceuticals Inc (NASDAQ: APLS) declined following a  
Via Benzinga
21 Analysts Have This to Say About Apellis Pharmaceuticals
November 02, 2023
 
Via Benzinga
Analyst Ratings for Apellis Pharmaceuticals
October 06, 2023
 
Via Benzinga
Apellis Pharmaceuticals to Host a Fireside Chat at the 6th Annual Evercore ISI HealthCONx Conference
November 21, 2023
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
NASDAQ:APLS Long Term Investor Notice: Investigation of Potential Wrongdoing at Apellis Pharmaceuticals, Inc.
November 14, 2023
San Diego, CA -- (SBWIRE) -- 11/14/2023 -- Certain directors of Apellis Pharmaceuticals, Inc. are under investigation on behalf of current long-term investors in shares of Apellis Pharmaceuticals, Inc.... 
Via SBWire
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 06, 2023
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Why Apellis Pharmaceuticals Stock Popped Today
October 05, 2023
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) shares are trading higher Thursday after the company reported preliminary U.S. 
Via Benzinga
SYFOVRE® (pegcetacoplan injection) Continued to Demonstrate Increasing Treatment Effects Over 3 Years in Patients with Geographic Atrophy (GA)
November 04, 2023
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
APELLIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Apellis Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
November 02, 2023
From Bragar Eagel & Squire
Via GlobeNewswire
Apellis Pharmaceuticals Reports Third Quarter 2023 Financial Results
November 01, 2023
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Inside Cathie Wood’s Portfolio: 3 Stocks She Is Betting Millions On
November 01, 2023
Are you looking to invest in disrupting stocks like Cathie Woods? Here are three stocks Cathie Wood is betting millions on. 
Via InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
October 31, 2023
 
Via Benzinga
Apellis Pharmaceuticals Stock Improves With An RS Ratings Over 90
October 31, 2023
Apellis Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating. 
Via Investor's Business Daily
Apellis Pharmaceuticals to Host Conference Call on November 1, 2023, to Discuss Third Quarter 2023 Financial Results
October 25, 2023
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Apellis Pharmaceuticals Stock Shows Rising Relative Strength
October 24, 2023
A Relative Strength Rating upgrade for Apellis Pharmaceuticals shows improving technical performance. Will it continue? 
Via Investor's Business Daily
The Lancet Publishes 24-Month Results from Phase 3 Studies of SYFOVRE® (pegcetacoplan injection) for Geographic Atrophy (GA)
October 20, 2023
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
10 Health Care Stocks Whale Activity In Today's Session
October 18, 2023
 
Via Benzinga
Apellis to Present Positive Phase 2 NOBLE Results of Pegcetacoplan in Post-Transplant Recurrence of Primary IC-MPGN and C3G at Kidney Week
October 17, 2023
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Stocks Mixed Amid Earnings, Consumer Sentiment Data
October 13, 2023
Stocks are mixed this afternoon, as investors unpack earnings reports from several bank giants as well as economic data. 
Via Talk Markets
JPMorgan, Wells Fargo, Citigroup And Other Big Stocks Moving Higher On Friday
October 13, 2023
U.S. stocks traded mostly higher, with the Dow Jones gaining more than 100 points on Friday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
Why Pioneer Natural Resources Shares Are Bouncing By Around 12%; Here Are 20 Stocks Moving Premarket
October 06, 2023
Gainers Vaccinex, Inc. (NASDAQ: VCNX) shares rose 40.2% to $1.15 in pre-market trading as two large insider buys were reported after the close on Thursday. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 6, 2023
October 06, 2023
 
Via Benzinga
Constellation Brands To Rally Over 20%? Here Are 10 Other Analyst Forecasts For Friday
October 06, 2023
HSBC raised the price target for Constellation Brands, Inc. (NYSE: STZ) from $280 to $290. HSBC analyst Carlos Laboy maintained a Buy rating. Constellation shares fell 3.2% to close at $241.33 on... 
Via Benzinga
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 05, 2023
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Apellis Announces Preliminary U.S. Net Revenues of Approximately $74 Million for SYFOVRE® (pegcetacoplan injection) in the Third Quarter of 2023
October 05, 2023
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
APLS DEADLINE TODAY: ROSEN, A LEADING NATIONAL FIRM, Encourages Apellis Pharmaceuticals, Inc. Investors to Secure Counsel Before Important October 2 Deadline in Securities Class Action - APLS
October 02, 2023
WHY: NEW YORK, NY - (NewMediaWire) - October 2, 2023 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) between... 
Via TheNewswire.com
Topics Lawsuit
< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
Recent Quotes
View More
Symbol Price Change (%)
GOOG  244.64
+7.15 (3.01%)
Site Logo
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap